ARWR – arrowhead pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
Alpha-1 Antitrypsin Deficiency Research Report 2025-2035: Market Enters Growth Phase as Established Augmentation Therapies Converge with Advancing Gene and RNA Pipelines [Yahoo! Finance]
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events [Yahoo! Finance]
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) was upgraded by analysts at Weiss Ratings from a "sell (d-)" rating to a "hold (c-)" rating.
Form 10-Q ARROWHEAD PHARMACEUTICAL For: Dec 31
Form 8-K ARROWHEAD PHARMACEUTICAL For: Feb 05
Form ARS ARROWHEAD PHARMACEUTICAL For: Jan 26
Form DEFA14A ARROWHEAD PHARMACEUTICAL
Form DEF 14A ARROWHEAD PHARMACEUTICAL For: Jan 26
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.